2024
Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer
Justice A, Tate J, Howland F, Gaziano J, Kelley M, McMahon B, Haiman C, Wadia R, Madduri R, Danciu I, Leppert J, Leapman M, Thurtle D, Gnanapragasam V. Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology 2024, 7: 923-932. PMID: 38171965, DOI: 10.1016/j.euo.2023.11.023.Peer-Reviewed Original ResearchVeterans Health AdministrationCharlson Comorbidity IndexNon-prostate cancer mortalityProstate cancer mortalityNonmetastatic prostate cancerComorbidity indexCancer mortalityProvider estimationProstate cancerHealth AdministrationUS Veterans Health AdministrationElectronic health record-based toolsYear of diagnosisRisk of deathObservational cohortMedian ageNonmetastatic cancerPredicting MortalityC-statisticHispanic ethnicityTreatment groupsMortalityCancerNational validationAge
2022
Circulating T Cells and Cardiovascular Risk in People With and Without HIV Infection
Kundu S, Freiberg MS, Tracy RP, So-Armah KA, Koethe JR, Duncan MS, Tindle HA, Beckman JA, Feinstein MJ, McDonnell WJ, Justice A, Doyle MF, Study V. Circulating T Cells and Cardiovascular Risk in People With and Without HIV Infection. Journal Of The American College Of Cardiology 2022, 80: 1633-1644. PMID: 36265959, DOI: 10.1016/j.jacc.2022.08.756.Peer-Reviewed Original ResearchConceptsT cell subsetsT helper type 17 (Th17) cellsCVD risk factorsIncident CVD eventsType 17 cellsIncident CVDCell subsetsHIV infectionCVD eventsRisk factorsInternational ClassificationT effector memory cellsRe-expressing CD45RAEffector memory cellsSubset of CD4Cardiovascular disease riskProportional hazards regressionT helper cellsMedian participant ageLow CD4Cardiovascular riskObservational cohortPrevalent CVDCVD incidenceRevision diagnosis
2019
Measuring Exposure to Incarceration Using the Electronic Health Record
Wang EA, Long JB, McGinnis KA, Wang KH, Wildeman CJ, Kim C, Bucklen KB, Fiellin DA, Bates J, Brandt C, Justice AC. Measuring Exposure to Incarceration Using the Electronic Health Record. Medical Care 2019, 57: s157-s163. PMID: 31095055, PMCID: PMC8352066, DOI: 10.1097/mlr.0000000000001049.Peer-Reviewed Original ResearchMeSH KeywordsAdministrative Claims, HealthcareAdultCohort StudiesElectronic Health RecordsEthnicityFemaleHumansInformation Storage and RetrievalMaleMedicareMiddle AgedNatural Language ProcessingPrisonersSelf ReportSensitivity and SpecificityUnited StatesUnited States Department of Veterans AffairsVeteransConceptsVeterans Aging Cohort StudyElectronic health recordsHuman immunodeficiency virus-infected patientsVHA electronic health recordsNational observational cohortVirus-infected patientsHealth recordsAging Cohort StudyEHR dataHealth care disparitiesAdministrative dataRace/ethnicityIncarceration exposureObservational cohortUninfected patientsCohort studySpecificity 99.3DATA SOURCESCare disparitiesSpecificity 100Specificity 98.9Social determinantsMedicaid ServicesSpecificity 95.9Health informationPredictors of timely opioid agonist treatment initiation among veterans with and without HIV
Wyse JJ, Robbins JL, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Gaither JR, Gordon K, Skanderson M, Barry DT, Crystal S, Justice A, Kraemer KL. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug And Alcohol Dependence 2019, 198: 70-75. PMID: 30878769, PMCID: PMC6836871, DOI: 10.1016/j.drugalcdep.2019.01.038.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyOAT initiationUninfected patientsClinical encountersNational observational cohortAging Cohort StudyAfrican American patientsImproved health outcomesAgonist therapyCohort studyObservational cohortTreatment initiationPredictive factorsEffective treatmentAdjusted modelUninfected controlsUse disordersPsychiatric diagnosisPWHClinical practicePatientsHealth outcomesRural residence
2017
Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study
Brittain EL, Duncan MS, Chang J, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Goetz M, Akgun K, Crothers K, Zola C, Kim J, Gibert C, Pisani M, Morris A, Hsue P, Tindle HA, Justice A, Freiberg M. Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study. American Journal Of Respiratory And Critical Care Medicine 2017, 197: 923-932. PMID: 29131651, PMCID: PMC6020408, DOI: 10.1164/rccm.201708-1555oc.Peer-Reviewed Original ResearchConceptsVeterans Aging Cohort StudyCD4 cell countHIV viral loadAging Cohort StudyUninfected veteransPulmonary pressurePrevalent comorbiditiesCohort studyViral loadHigh prevalenceCell countLow CD4 cell countsHigher HIV viral loadAntiretroviral therapy eraRisk of deathRace/ethnicityPASP valuesTherapy eraAdjusted riskPulmonary hypertensionObservational cohortPrognostic impactPrimary outcomeClinical featuresHIV statusAssociation Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study
Freiberg MS, Chang CH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Vasan RS, Oursler KA, Gottdiener J, Gottlieb S, Leaf D, Rodriguez-Barradas M, Tracy RP, Gibert CL, Rimland D, Bedimo RJ, Brown ST, Goetz MB, Warner A, Crothers K, Tindle HA, Alcorn C, Bachmann JM, Justice AC, Butt AA. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiology 2017, 2: 536-546. PMID: 28384660, PMCID: PMC5541383, DOI: 10.1001/jamacardio.2017.0264.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCase-Control StudiesCD4 Lymphocyte CountCohort StudiesFemaleHeart FailureHIV InfectionsHumansMaleMiddle AgedProportional Hazards ModelsRisk AssessmentRisk FactorsRisk Reduction BehaviorStroke VolumeUnited StatesUnited States Department of Veterans AffairsVeteransViral LoadConceptsRisk of HFrEFHuman immunodeficiency virus (HIV) infectionVeterans Aging Cohort StudyAntiretroviral therapy eraRisk of HFpEFReduced ejection fractionCells/mm3Immunodeficiency virus infectionHeart failureAging Cohort StudyHIV infectionEjection fractionUninfected veteransTherapy eraCohort studyVirus infectionHIV-1 RNA viral loadTime-updated CD4 cell countHIV-specific factorsBaseline cardiovascular diseaseCD4 cell countRNA viral loadCopies/mLRace/ethnicityObservational cohort
2016
D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events
Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O’Bryan T, Rimland D, Justice AC, Agan BK, . D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLOS ONE 2016, 11: e0152588. PMID: 27088215, PMCID: PMC4835105, DOI: 10.1371/journal.pone.0152588.Peer-Reviewed Original ResearchConceptsNon-AIDS diseasesNon-AIDS eventsD-dimer levelsHIV viral suppressionART initiationAntiretroviral therapyViral suppressionD-dimerInterleukin-6Time pointsUS Military HIV Natural History StudyMulticenter observational cohortMedian CD4 countIL-6 levelsMean percent increaseActive duty military personnelNatural history studiesDuty military personnelCD4 countHIV seroconversionHIV levelsMedian durationObservational cohortMedian timeExcess risk
2013
Validation of an algorithm to identify antiretroviral‐naïve status at time of entry into a large, observational cohort of HIV‐infected patients
Gandhi NR, Tate JP, Rodriguez‐Barradas M, Rimland D, Goetz MB, Gibert C, Brown ST, Mattocks K, Justice AC. Validation of an algorithm to identify antiretroviral‐naïve status at time of entry into a large, observational cohort of HIV‐infected patients. Pharmacoepidemiology And Drug Safety 2013, 22: 1019-1025. PMID: 23836591, PMCID: PMC3831617, DOI: 10.1002/pds.3476.Peer-Reviewed Original ResearchConceptsART-naïve patientsViral load thresholdMedical record reviewAntiretroviral treatmentMedical recordsHIV cohortObservational cohortRecord reviewVeterans Aging Cohort Study Virtual CohortVirtual cohortPrevious antiretroviral treatmentLaboratory dataPatients' medical recordsPositive predictive value 87Cohort entryAdverse eventsHIV outcomesRandomized trialsRetrospective studyAdverse reactionsTime of entryCopies/ART treatmentTreatment statusTreatment history
2009
Hepatitis C Virus Infection and the Risk of Coronary Disease
Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C Virus Infection and the Risk of Coronary Disease. Clinical Infectious Diseases 2009, 49: 225-232. PMID: 19508169, PMCID: PMC3077953, DOI: 10.1086/599371.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseHepatitis C virus infectionC virus infectionTraditional risk factorsHigh riskHCV infectionControl subjectsRisk factorsVirus infectionRisk of CADMean total plasma cholesterolLow-density lipoprotein cholesterolCox proportional hazards modelHCV Infected VeteransTotal plasma cholesterolFavorable risk profileProportional hazards modelVeterans Affairs facilitiesLower lipid levelsLipoprotein cholesterolObservational cohortRenal failureArtery diseaseCoronary diseaseMultivariable analysisThe Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication
Freiberg MS, Leaf DA, Goulet JL, Goetz MB, Oursler KK, Gibert CL, Rodriguez-Barradas MC, Butt AA, Justice AC. The Association Between the Receipt of Lipid Lowering Therapy and HIV Status Among Veterans Who Met NCEP/ATP III Criteria for the Receipt of Lipid Lowering Medication. Journal Of General Internal Medicine 2009, 24: 334-340. PMID: 19127386, PMCID: PMC2642578, DOI: 10.1007/s11606-008-0891-7.Peer-Reviewed Original ResearchConceptsNCEP/ATP III criteriaATP III criteriaHIV viral loadViral loadAdult Treatment Panel guidelinesHigher HIV viral loadFive-site studyLipid lowering medicationsVeterans Aging CohortHIV infection statusLipid-Lowering TherapyProspective observational cohortCross-sectional analysisHIV-HCVLowering therapiesModifiable mediatorsObservational cohortResultsThe prevalenceHIV infectionHIV statusPharmacy dataCardiovascular diseasePanel guidelinesMAIN OUTCOMELow prevalence
2007
Estimating the impact of alcohol consumption on survival for HIV+ individuals
Braithwaite RS, Conigliaro J, Roberts MS, Shechter S, Schaefer A, McGinnis K, Rodriguez MC, Rabeneck L, Bryant K, Justice AC. Estimating the impact of alcohol consumption on survival for HIV+ individuals. AIDS Care 2007, 19: 459-466. PMID: 17453583, PMCID: PMC3460376, DOI: 10.1080/09540120601095734.Peer-Reviewed Original ResearchConceptsAlcohol consumptionFrequency of consumptionDaily consumptionModifiable risk factorsLarge observational cohortHazardous alcohol consumptionDose-response relationshipImpact of alcoholHIV diseaseObservational cohortOverall survivalAntiretroviral adherencePoor outcomeRisk factorsPoor survivalClinical dataHazardous drinkersNonhazardous drinkersAdherence resultsAlcohol's impactSurvivalWeeksDrinkersAdherenceYears
2005
Estimating the proportion of patients infected with HIV who will die of comorbid diseases
Braithwaite RS, Justice AC, Chang CC, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. The American Journal Of Medicine 2005, 118: 890-898. PMID: 16084183, DOI: 10.1016/j.amjmed.2004.12.034.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusComorbid diseasesCombination therapyNaïve human immunodeficiency virusNon-HIV mortalityEffective antiretroviral therapyCells/mm3Proportion of patientsSeparate patient cohortsCopies/mLProportion of deathsLikelihood of deathAntiretroviral therapyObservational cohortHIV infectionTreatment failureViral loadImmunodeficiency virusMean agePatient cohortPatientsSubsequent deathPhenotypic resistanceTherapyCohort
2003
Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era
King JT, Justice AC, Roberts MS, Chang CC, Fusco JS. Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era. Medical Decision Making 2003, 23: 9-20. PMID: 12583451, DOI: 10.1177/0272989x02239652.Peer-Reviewed Original ResearchConceptsCells/mm3Long-term survivalCD4 cell countAge-associated mortalityTreatment failureHIV/AIDSUS life tablesCell countActive antiretroviral therapy (HAART) eraBaseline CD4 cell countHIV/AIDS patientsLong-term survival dataShort-term survival dataAntiretroviral therapy eraPre-HAART cohortTreatment mortality rateActive antiretroviral therapyTreatment failure rateRisk of mortalitySurvival dataShort-term survivalHAART failureTherapy eraAntiretroviral therapyObservational cohort